Paul Zamecnik dies

Paul Zamecnik, a Lasker award-winning biologist who co-discovered transfer RNA, died late last month at the age of 96. Zamecnik died at his Boston home after battling cancer. Paul ZamecnikImage: Massachusetts General HospitalIn the mid-1950s, along with molecular biologists Mahlon Hoagland and Mary Stephenson, Zamecnik linkurl:discovered;http://www.ncbi.nlm.nih.gov/pubmed/13538965?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=123 the molecule responsible for

Written byBob Grant

| 2 min read

Save for Later

Paul Zamecnik, a Lasker award-winning biologist who co-discovered transfer RNA, died late last month at the age of 96. Zamecnik died at his Boston home after battling cancer.

Paul Zamecnik
Image: Massachusetts General Hospital

In the mid-1950s, along with molecular biologists Mahlon Hoagland and Mary Stephenson, Zamecnik linkurl:discovered;http://www.ncbi.nlm.nih.gov/pubmed/13538965?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=123 the molecule responsible for transporting amino acids to ribosomes during protein synthesis, which the trio dubbed transfer RNA (tRNA). Little was known about the mechanism of protein synthesis up to that point. The team's discovery was made possible through the development of an in vitro protein synthesis modeling system in which Zamecnik used C¹⁴-labeled amino acids to observe peptide bond formation. The paper announcing the discovery of tRNA, published in 1958, has been cited more than 620 times, according to ISI's Web of Knowledge. Later in his career, Zamecnik and Stephenson developed antisense technology, in which short, synthetic nucleotide sequences can be used to silence the activity of individual genes. They linkurl:published;http://www.ncbi.nlm.nih.gov/pubmed/75545?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=63 their results, in which they used a 13-nucleotide sequence to halt production of Rous sarcoma virus in chicken embryos, in 1978. That paper, which appeared in __Proceedings of the National Academy of Sciences__, has been cited more than 900 times, according to ISI. Since then, researchers have explored antisense technology as a treatment approach for a variety of diseases, from viral infections and cancer to cardiovascular, autoimmune, and inflammatory diseases. One antisense drug, Isis Pharmaceutical's Vitravene, was commercialized in 1998 to treat cytomegalovirus retinitis in AIDS patients, and several others are in clinical trials. Born in 1912, Zamecnik was "a Cleveland kid," according to his linkurl:biography;http://www.laskerfoundation.org/learn/con_zamecnik.htm on the Lasker Foundation's website. Schooled as a physician, Zamecnik decided to devote his career to research while serving as an intern at University Hospitals in Cleveland in the late 1930s. The death of an obese patient, who had an overabundance of fat and a fatal dearth of protein, led him to question the process of protein synthesis. Zamecnik said in an linkurl:interview;http://www.laskerfoundation.org/learn/zamecnik_text.htm featured on the Lasker website that the episode made him wonder how proteins were made in the body and how that process was regulated. "And I asked the people in medicine at the University Hospitals, 'Who is studying protein synthesis?' And they all shook their heads." Almost six decades later, in 1996, Zamecnik was awarded the Albert Lasker Award for Special Achievement in Medical Science "for brilliant and original science that revolutionized biochemistry and spawned new avenues of scientific inquiry." "Paul was a remarkable person to me," said Hoagland (who linkurl:died;http://www.the-scientist.com/blog/display/56025/ earlier this year) in Zamecnik's Lasker Foundation biography. "He created a laboratory atmosphere that was very informal, very relaxed, very good fun, and very little pressure of competition in the laboratory. I think his whole attitude contributed significantly to an openness and sharing which, in turn, contributed to the success of the laboratory." Zamecnik published more than 240 scientific papers during his career and is survived by two daughters, Karen Zamecnik and Elizabeth Coakley, one son, John, seven grandchildren, and two great-grandchildren.
**__Related stories:__***linkurl:Mahlon Hoagland dies;http://www.the-scientist.com/blog/display/56025/
[29th September 2009]*linkurl:50 Years Ago in Biochemistry;http://www.the-scientist.com/article/display/54255/
[February 2008]*linkurl:Making Sense of Antisense;http://www.the-scientist.com/article/display/18172/
[31st August 1998]

Meet the Author

Bob Grant

From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

View Full Profile

Paul Zamecnik dies

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies